Managing cardiovascular risk in patients with HIV infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 38, Issue 2, 2005, Pages 115-123

  Stein, James H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Antiviral therapy; Cardiovascular disease; HIV; Lipoproteins; Protease inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; PRAVASTATIN; PROTEASOME; PROTEINASE INHIBITOR; RITONAVIR; ROSUVASTATIN; SAQUINAVIR; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; DYSLIPIDEMIA; FAMILY HISTORY; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIFESTYLE; LYMPHOCYTE COUNT; MORTALITY; OBESITY; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; SMOKING;

ANTILIPEMIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HIV INFECTIONS; HUMANS; HYPERLIPIDEMIAS; LIPIDS; PRACTICE GUIDELINES; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 13244249850     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000147525.26746.07     Document Type: Review

References (59)

1. Sepkowitz K. AIDS-the first 20 years. N Engl J Med. 2001;344:1764-1772.
2. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
3. Palella F, Deloria-Knoll M, Chmiel J, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern. Med. 2003;138:620-626.
4. Bozzette S, Ake C, Tam H, et al. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.
5. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
6. Shelton D. Changing demographics in HIV infections. 2000. Available at: http://www.ama-assn.org/amednews/2000/10/23/hisa1023.htm.
7. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 1998;12(Suppl):F51-F58.
8. Dube M, Sattler F. Metabolic complications of antiretroviral therapies. AIDS Clin Care. 1998;10:41-44.
9. SoRelle R. Vascular and lipid syndromes in selected HIV-infected patients. Circulation. 1998;98:829-830.
10. Tabib A, Greenland T, Mercier I, et al. Coronary lesions in young HIV-positive subjects at necropsy. Lancet. 1992;340:730.
11. Constans J, Marchand J-M, Conn C, et al. Asymptomatic atherosclerosis in HIV-positive patients: a case-control ultrasound study. Ann Med. 1995;27:683-685.
12. Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet. 1998;351:1958-1959.
13. Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet. 1998;351:1328.
14. Klein D, Hurley L, Quesenberry J, et al. Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr. 2002;30:471-477.
15. Klein D, Hurley L, Quesenberry J, et al. Hospitalization for coronary heart disease and myocardial infarction among men with HIV-1 infection: follow-up through 12/31/03. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
16. Mary-Krause M, Cotte L, Simon A, et al. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS. 2003;17:2479-2486.
17. Currier J, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr. 2003;33:506-512.
18. Chironi G, Escaut L, Gariepy J, et al. Brief report: carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr. 2003;32:490-493.
19. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals-focus on protease inhibitor therapy. AIDS. 2001; 15:329-334.
20. Maggi P, Serio G, Epifani G, et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease inhibitors. AIDS. 2000;14 (Suppl):FI23-FI28.
21. Meng Q, Lima J, Lai H, et al. Coronary artery calcification, atherogenic lipid changes, and increased erythrocyte volume in black injection drug users infected with human immunodeficiency virus-1 treated with protease inhibitors. Am Heart J. 2002;144:642-648.
22. Mercie P, Thiebaut R, Lavignolle V, et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med. 2002;34:55-63.
23. Seminari E, Pan A, Voltini G, et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis. 2002;162:433-438.
24. Hsue P, Lo J, Franklin A, et al. Increased atherosclerotic progression in patients with HIV: the role of traditional and immunologic risk factors. Presented at the 10th Conference on Retroviruses and Opportunistic Infections; 2003; Boston.
25. Dube M, Shanker S, Vanderluitgaren J, et al. Effect of indinavir (IDV) monotherapy on endothelial function in men without HIV infection. Presented at the Ninth Conference on Retroviruses and Opportunistic Infections; 2002; Seattle.
26. Monsuez J, Dufaux J, Jittecoq D, et al. Reduced reactive hyperemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2000;25:434-442.
27. Nolan D, Watts G, Herrmann S, et al. Endothelial function in HIV-infected patients receiving protease inhibitor therapy: does immune competence affect cardiovascular risk? QJM. 2003;96:825-832.
28. Stein J, Klein M, Bellehumeur J, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
29. Holmberg S, Moorman A, Williamson J, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet. 2002;360:1747-1748.
30. Iloeja U, Yuan Y, et al. Protease inhibitor (PIs) exposure time and risk of cardiovascular disease (CVD) in human immunodeficiency virus (HIV) infected patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections; 2004; San Francisco.
31. Friis-Moller N, Sabin C, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349: 1993-2003.
32. Stein J. Dyslipidemia in the era of HIV protease inhibitors. Prog Cardiovasc Dis. 2003;45:293-304.
33. Hui D. Effects of HIV protease inhibitor therapy on lipid metabolism. Prog Lipid Res. 2003;42:81-92.
34. Dube M, Stein J, Aberg J, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis. 2003;37:613-627.
35. Executive Summary. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
36. Grundy S. Primary prevention of coronary heart disease: integrating risk assessment with intervention. Circulation. 1999;100:988-998.
37. Grundy S, Pasternak R, Greenland P, et al. Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 1999;100:1481-1492.
38. Lloyd-Jones D, Larson M, Beiser A, et al. Lifetime risk of developing coronary heart disease. Lancet. 1999;353:89-92.
39. Otvos J. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. In: Nader Rifai MHD, Wamick GR, eds. Handbook of Lipoprotein Testing. 2000, Washington, DC: AACC Press; 2000:609-624.
40. Otvos J. Why cholesterol measurements may be misleading about lipoprotein levels and cardiovascular disease risk-clinical implications of lipoprotein quantifications using NMR spectroscopy. Laboratoriums Medizin. 2002;26:544-550.
41. Riddler S, Smit E, Cole S, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA. 2003;289:2978-2982.
42. Carr A, Miller J, Law M, et al. A syndrome of lipoatrophy, lactic acidemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease-inhibitor-related lipodystrophy syndrome. AIDS. 1998;12(Suppl):F51-F58.
43. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
44. Saag MS, Powderly WG, Schambelan M, et al. Switching antiretroviral drugs for treatment of metabolic complications in HIV-1 infection: summary of selected trials. Top HIV Med. 2002;10:47-51.
45. Lee I. Physical activity in women: how much is good enough? JAMA. 2003;290:1377-1379.
46. Williams P. Physical fitness and activity as separate heart disease risk factors: a meta-analysis. Med Sci Sports Exerc. 2001;33:754-761.
47. Hu F, Willett W. Optimal diets for prevention of coronary heart disease. JAMA. 2002;288:2569-2578.
48. de Lorgeril M, Salen P, Martin J, et al. Mediterranean dietary pattern in a randomized trial: prolonged survival and possible reduced cancer rate. Arch Intern Med. 1998;158:1181-1187.
49. de Lorgeril M, Salen P, Martin J, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. Circulation. 1999; 99:779-785.
50. Singh R, Dubnov G, Niaz M, et al. Effect of an Indo-Mediterranean diet on progression of coronary artery disease in high risk patients (Indo-Mediterranean Diet Heart Study): a randomised single-blind trial. Lancet. 2002;360:1455-1461.
51. Knowler W, Barrett-Connor E, Fowler S, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
52. Tuomilehto J, Lindstrom J, Eriksson J, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-1350.
53. Aberg J, Zackin R, Evans S, et al. A prospective, multicenter, randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. Presented at the XIV International AIDS Conference; 2002; Barcelona.
54. Ballantyne C, Davidson M. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med. 2003;163: 2394-2395.
55. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-23.
56. Sever P, Dahlof B, Poulter N, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149-1158.
57. Cannon C, Braunwald E, McCabe C, et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
58. Nissen S, Tuzcu E, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291:1071-1080.
59. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. Circulation. 2004;110:227-239.